AstraZeneca: termines anti-cholesterol program with Ionis
(CercleFinance.com) - Ionis Pharmaceuticals announced on Friday that AstraZeneca had decided not to pursue the development of the PCSK9 program in hypercholesterolemia following phase 2b results that were deemed to be mixed.
In a statement, Ionis said the study showed a "significant" reduction in LDL-C cholesterol at 28 weeks compared to placebo, meeting its primary efficacy endpoint.
However, the Californian biotech company notes that the trial failed to meet certain predefined efficacy endpoints, leading AstraZeneca to abandon the launch of a phase 3 clinical trial.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
In a statement, Ionis said the study showed a "significant" reduction in LDL-C cholesterol at 28 weeks compared to placebo, meeting its primary efficacy endpoint.
However, the Californian biotech company notes that the trial failed to meet certain predefined efficacy endpoints, leading AstraZeneca to abandon the launch of a phase 3 clinical trial.
Copyright (c) 2022 CercleFinance.com. All rights reserved.